ACTRN12606000042549尚未招募不适用
A randomised phase III study evaluating the effectiveness and cost utility of the Minimum Dataset- Home Care (MDS-HC) assessment tool in comparison to the existing Needs and Service Coordination (NASC) assessment process to improve the quality of life for older people in the community requiring these assessment services.
Ministry of Health, New Zealand0 个研究点目标入组 320 人开始时间: 2006年1月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 65 Years 至 ot stated（—）
- 性别
- All
入选标准
- •1.Males and females aged 65 or greater years on the day of baseline examination; or aged 55 if of Mäori or Pacific Ethnicity and eligible for NASC/ OPAT services.2.All participants must be eligible for assessment by the three designated MDS-HC assessors.
排除标准
- •1.Those clients with a terminal illness and are currently receiving palliative care services2.Participants directly transferred from hospital to permanent residential care after the initial assessment.
研究者
相似试验
招募中
3 期
Early inpatient-outpatient hospital-based pulmonary rehabilitation following hospitalisation for acute exacerbations of COPD: a randomised controlled studyChronic Obstructive Pulmonary Disease (COPD)Respiratory - Chronic obstructive pulmonary diseasePhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12605000372684Green Lane Research and Educational Fund100
进行中（未招募）
不适用
Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer. - Neostaton-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10025050Term: Lung cancer non-small cell stage IMedDRA version: 9.1Level: LLTClassification code 10025051Term: Lung cancer non-small cell stage IIMedDRA version: 9.1Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage IIIMedDRA version: 9.1Level: LLTClassification code 10025053Term: Lung cancer non-small cell stage IIIAEUCTR2007-000903-14-GBImperial College, London184
已完成
3 期
PROphylaxis of ThromboEmbolism in Critical Care Trial (PROTECT)ThromboembolismCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12606000090516McMaster University3,650
已完成
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in elderly patients with previously untreated systemic peripheral T-cell lymphomasT-cell lymphoma10025321NL-OMON41578niversity Medicine Goettingen25
尚未招募
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomasT cell lymphoma10025321NL-OMON31642ordic Lymphoma Group40